A
Andreas Reiff
Researcher at Children's Hospital Los Angeles
Publications - 90
Citations - 7035
Andreas Reiff is an academic researcher from Children's Hospital Los Angeles. The author has contributed to research in topics: Juvenile rheumatoid arthritis & Lupus erythematosus. The author has an hindex of 40, co-authored 89 publications receiving 6518 citations. Previous affiliations of Andreas Reiff include University of Southern California.
Papers
More filters
Journal ArticleDOI
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Daniel J. Lovell,Edward H. Giannini,Andreas Reiff,Gail Cawkwell,Earl D. Silverman,James J. Nocton,Leonard D. Stein,Abraham Gedalia,Norman T. Ilowite,Carol A. Wallace,James B Whitmore,Barbara K. Finck +11 more
TL;DR: Treatment with etanercept leads to significant improvement in patients with active polyarticular juvenile rheumatoid arthritis and is well tolerated by pediatric patients.
Journal ArticleDOI
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Daniel J. Lovell,Nicolino Ruperto,Steven N. Goodman,Andreas Reiff,Lawrence Jung,Katerina Jarosova,Dana Nemcova,Richard Mouy,Christy Sandborg,John F. Bohnsack,Dirk Elewaut,Ivan Foeldvari,Valeria Gerloni,Jozef Rovensky,Kirsten Minden,Richard K. Vehe,L. Wagner Weiner,Gerd Horneff,Hans Iko Huppertz,Nancy Y. Olson,John R. Medich,Roberto Carcereri-De-Prati,Melissa J. McIlraith,Edward H. Giannini,Alberto Martini +24 more
TL;DR: Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis.
Journal ArticleDOI
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
Daniel J. Lovell,Andreas Reiff,Andreas Reiff,Norman T. Ilowite,Carol A. Wallace,Yun Chon,Shao Lee Lin,Scott Baumgartner,Edward H. Giannini +8 more
TL;DR: These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients.
Journal ArticleDOI
Etanercept therapy in children with treatment-resistant uveitis.
Andreas Reiff,Syuji Takei,Syuji Takei,Said Sadeghi,Ann U. Stout,Ann U. Stout,Bracha Shaham,Bram H. Bernstein,Kerry Gallagher,Timothy J. Stout +9 more
TL;DR: The data suggest that etanercept injected subcutaneously twice a week has a beneficial effect on treatment-resistant chronic uveitis in children.
Journal ArticleDOI
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Daniel J. Lovell,Edward H. Giannini,Andreas Reiff,Olcay Y. Jones,Rayfel Schneider,Judyann C. Olson,Leonard D. Stein,Abraham Gedalia,Norman T. Ilowite,Carol A. Wallace,Mary Lange,Barbara K. Finck,Daniel Burge +12 more
TL;DR: Children with severe, longstanding, methotrexate-resistant polyarticular JRA demonstrated sustained clinical improvement with >2 years of continuous etanercept treatment.